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Abstract
Background: Donor human hearts cannot be preserved for >5 hours
between explantation and recipient implantation. A better approach is needed
to preserve transplantable hearts for longer periods, ideally at ambient
conditions for transport. We tested whether Lifor solution could satisfactorily
preserve guinea pig isolated hearts perfused at low flow with no added
oxygen at room temperature for 20 hours.
Methods: Hearts were isolated from 18 guinea pigs and perfused initially
with oxygenated Krebs–Ringer (KR) solution at 37°C. Hearts were then
perfused with recirculated Lifor or cardioplegia (CP) solution (K + 15
mmol/liter) equilibrated with room air at 20% of control flow at 26°C for 20
hours. Hearts were then perfused at 100% flow with KR for 2 hours at 37°C.
Results: Lifor and CP arrested all hearts. During the 20-hour low-flow
perfusion with Lifor coronary pressure increased by 6 ± 2 mm Hg and percent
oxygen extraction by 29 ± 2%, whereas oxygen consumption (MVo 2)
decreased by 74 ± 4%. Similar changes were noted for CP, except that MVo2
was decreased by 86 ± 7%. After 20-hour low-flow perfusion with Lifor and 2
hours of warm reperfusion with KR solution, diastolic left ventricular pressure
(LVP), maximal dLVP/dt and percent oxygen extraction returned completely
to baseline values, whereas heart rate returned to 80 ± 3%, developed LVP to
76 ± 3%, minimal dLVP/dt (relaxation) to 65 ± 4%, coronary flow to 80 ±
4%, oxygen consumption to 82 ± 4% and cardiac efficiency to 85 ± 4% of
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baseline values. Flow responses to adenosine and nitroprusside after Lifor
treatment were 65 ± 3% and 64 ± 3% of their baseline values. After
cardioplegia, treatment there was no cardiac activity, with a diastolic pressure
of 35 ± 14 mm Hg and a return of coronary flow to only 45 ± 3% of baseline
value.
Conclusions: Compared with a cardioplegia solution at ambient air and
temperature conditions, Lifor solution is a much better medium for long-term
cardiac preservation in this model.
In cardiac transplantation, the transport time between harvest and
recipient implantation is limited by the viability of the donor heart. Cold
storage of human hearts for transplantation currently limits functional viability
to 4 to 5 hours despite development and clinical availability of approximately
10 different heart preservation solutions. There remains a lack of consensus
on the ideal solution. Two major problems with current approaches are the
need for severe hypothermia (3° to 6°C) and the lack of tissue perfusion
during transport. Very low-flow perfusion of hearts at room temperature
without supplemental oxygen would facilitate a lengthening of the period of
viability and reduce the need for complicated support equipment during
transport. To do so requires a suitable preservation solution. Lifor is a fully
artificial preservation medium containing both a non-protein oxygen and
nutrient carrier (nanoparticles) and cellular nutrients, including amino acids
and sugars. Our aim was to compare a cardioplegia (CP) solution with Lifor
solution when recirculated into hearts at room temperature and atmospheric
conditions for 20 hours. Our aim was to determine whether Lifor was more
effective than CP in preserving cardiac electrical, mechanical, vascular and
metabolic function on restitution with a normal physiologic crystalloid
solution.

Methods
Langendorff Heart Preparation
The present investigation conformed to the Guide for the Care
and Use of Laboratory Animals (NIH publication 85-23, revised 1996).
Prior approval was obtained from the institutional biomedical resource
committee. Our Langendorff heart method has been described
previously in detail.1–5 Isolated hearts were perfused with in-linefiltered (20-µm pore) and oxygenated (pH 7.39 ± 0.1, Po2 562 ± 11
mm Hg) Krebs–Ringer (KR) solution containing (in millimoles per
liter): 137 Na+, 5 K+, 1.2 Mg2+, 2.5 Ca2+, 134 Cl−, 15.5 HCO3− 1.2
Journal of Heart and Lung Transplantation, Vol. 27, No. 9 (September 2008): pg. 1008-1015. DOI. This article is © Elsevier
and permission has been granted for this version to appear in e-Publications@Marquette. Elsevier does not grant
permission for this article to be further copied/distributed or hosted elsewhere without the express permission from
Elsevier.

3

NOT THE PUBLISHED VERSION; this is the author’s final, peer-reviewed manuscript. The published version may be
accessed by following the link in the citation at the bottom of the page.

H2PO4−, 11.5 glucose, 2 pyruvate, 16 mannitol and 0.05 ethylenediamine tetraacetic acid (EDTA), with 5 units/liter insulin. Perfusate
temperature was maintained at 37.2 ± 0.1°C before and after CP (n =
7 hearts) or Lifor treatment (n = 11 hearts).
Lifor (Lifeblood Medical, Inc., Freehold, NJ) is a proprietary (U.S.
Patent #7,220,538) solution containing sugars, amino acids, salts,
buffers, colloids and lipid nanoparticles, as defined in the patent. The
CP and Lifor solutions had the following compositions, respectively,
when equilibrated with room air at 26°C: 295 ± 4 and 297 ± 5
mOsm/liter; pH 7.07 ± 0.01 and 7.08 ± 0.01; Pco2 5.0 ± 0.2 and 6.0
± 0.3 mm Hg; Po2 169 ± 2 and 167 ± 3 mm Hg; Na+ 136 ± 2 and 98
± 1 mmol/liter; K+ 15.1 ± 0.4 and 15.8 ± 0.5 mmol/liter; and Ca2+
0.25 ± 0.03 and 0.17 ± 0.02 mmol/liter. Lifeblood Medical had no role
in the collection, analysis and interpretation of data or the right to
approve or disapprove its publication. Additives to CP and Lifor were
10 µmol/liter adenosine and 1 µmol/liter blebbistatin, a myosin II
inhibitor.6,7 Bartel’s antibotic solution (3%, containing gentamycin,
streptomycin and amphotericin B) was also added to the preservation
solutions because hearts were not harvested in a sterile manner and
the solution was exposed to room air. During the 20-hour treatment
period with 250 ml of recirculated CP or Lifor, coronary inflow was set
at 15% to 20% of the baseline flow of approximately 17 ml/min, so
that this volume was recirculated through the vasculature
approximately 12 times. Recirculation was achieved using pump and
tubing between the right ventricle (coronary sinus) and aortic inflow
(coronary ostia) cannula.
Left ventricular pressure (LVP) and its first derivative (dLVP/dt)
were measured isovolumetrically with a transducer and a saline-filled
balloon inserted into the LV through the mitral valve. Balloon volume
was initially adjusted to a diastolic LVP of 0 mm Hg so that any
subsequent increase in diastolic LVP reflected diastolic contracture.
Heart rate was monitored from bipolar electrodes in the right atrial
appendage and right ventricular free wall. Coronary flow was
measured by an ultrasonic flowmeter placed into the aortic in-flow line.
Coronary sinus effluent was collected from a catheter placed into the
right ventricle through the pulmonary artery after ligating both venae
cavae. Coronary effluent Na+, K+, Ca2+, Po2, Pco2 and pH were
measured intermittently. Coronary outflow (sinus) oxygen tension was
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also measured in-line with a Clark-type oxygen electrode. Percent
oxygen extraction was calculated as 100 · (Pao2 − PVo2)/Pao2 (where
Pao2 and PVo2 are arterial and venous Po2, respectively). Myocardial
oxygen consumption (MVo2) was calculated as (coronary flow/g) ·
(arterial Pao2 − PVo2) · 24 µl O2/ml (37°C) or 26.5 µl O2/ml (26°C) at
760 mm Hg; and cardiac work efficiency was calculated as: systolic–
diastolic LVP · heart rate/MVo2.
All data were collected from hearts in sinus rhythm at baseline.
After the 20-hour treatment period and a 2-hour reperfusion period
with KR, hearts were removed and the ventricles were cut into 4 or 5
horizontal sections and stored overnight in 10% formaldehyde. Wet
heart weight was 1.46 ± 0.07 g averaged for both groups. Ventricular
infarct size (percent of total ventricular weight) was determined by one
of the investigators (J.S.H.) without knowledge of the treatment, using
the 2,3,5-triphenyltetrazolium chloride (TTC) staining method.3,5

Protocol
Each experiment lasted 23 hours, beginning after 30 minutes of
equilibration. Ten-second recordings of atrial and ventricular
electrograms, LVP, coronary flow, venous Po2, perfusion pressure and
temperature were recorded automatically every 30 minutes
(PowerLab, ADInstruments, info@adinstruments.com). There was no
time-control group. We previously reported a comparison of Lifor and
ViaSpan treatments for 10 hours to a time-control group.5 Because the
ViaSpan-treated groups were non-viable, in the present study we
compared the Lifor treatment with a cardioplegia treatment. Hearts
were allowed to cool from 37°C to 26.2 ± 0.05°C over 10 minutes at
the initiation of treatment and were rewarmed from 26.2°C to 37°C
over 10 minutes on reperfusion with KR as during baseline conditions
(Figure 1A). LVP, coronary flow and coronary venous Po2 were
measured continuously before, during and after treatment. Hearts
arrested immediately with CP or Lifor treatments.
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Figure 1

(A) Cardiac temperature before, during and after treatment with air-

equilibrated, recirculated CP or Lifor solution for 20 hours at 20% baseline flow. (B)
Both treatment-arrested hearts; after treatment, CP treated hearts did not beat. Heart
rate in the Lifor-treated group was lower than before treatment.

Statistical Analysis
All data are presented as mean ± SEM. Data were analyzed by
1-way (within-group) analysis of variance (SuperANOVA 1.11; Abacus
Concepts, Berkeley, CA) for comparison of data collected at the
selected time-points of 10 and 20 hours (during treatment) and 22
hours (2 hours after treatment) vs that at 0 hours (37°C pretreatment
baseline). Two-way analysis of variance (between groups) was
determined at these same time-points. If F-values from the analyses
of variance were significant, Duncan’s and least-significant-difference
(LSD) post hoc tests were used to clarify differences over time and
between the two groups (p < 0.05, 2-tailed).

Results
CP and Lifor solutions arrested all hearts (Figure 1B). Each heart
in the CP-treated group exhibited no electrical or contractile activity on
reperfusion 22 hours later with KR solution, whereas each Lifor-treated
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heart had rhythmic contractions on reperfusion. None of the Lifortreated hearts exhibited ventricular dysrhythmias throughout the posttreatment period. Two hours after terminating Lifor treatment, heart
rate was 20 ± 3% lower than baseline and developed (systolic–
diastolic) LVP (Figure 2A) returned to 76 ± 3% of baseline values after
2-hour reperfusion. Diastolic LVP (Figure 2B) remained very low on
reperfusion with KR in the Lifor group, but diastolic contracture (35 ±
14 mm Hg) occurred in the CP group. With 2-hour reperfusion,
minimal dLVP/dt, an index of relaxation (Figure 3A), returned to 65 ±
4%, whereas maximal dLVP/dt, an index of contractility (Figure 3B),
returned to 100 ± 3% of baseline values in the Lifor group.

Figure 2

(A) Developed (systolic–diastolic) left ventricular pressure (LVP) was near

zero after CP treatment and reduced after Lifor treatment. (B) Diastolic LVP was not
altered during or after Lifor treatment but was markedly increased after CP treatment.
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Figure 3

(A) Minimal dLVP/dt was lower after treatment with air-equilibrated, re-

circulated Lifor for 20 h at 26°C at 20% baseline coronary flow. (B) Maximal dLVP/dt
was fully restored after Lifor treatment. CP-treated hearts exhibited no contractility or
relaxation.

Coronary flow (Figure 4A) was set constant (2.0 ± 0.4
ml/g/min) at 20% of the baseline flow (10 ± 2 ml/g/min) during CP
and Lifor treatments. On reperfusion after Lifor, coronary flow returned
to 80 ± 4% of the baseline value, but to only 45 ± 3% of baseline
after CP. Coronary perfusion pressure was set to 55 ± 2 mm Hg before
and after CP or Lifor treatments. Constant flow perfusion pressure
(Figure 4B) increased slightly from 4 ± 1 to 10 ± 2 mm Hg between 1
and 20 hours in both groups and was higher on reperfusion after CP
than after Lifor. Responses to adenosine and nitroprusside (Figure 5A)
were lower by 35 ± 3% and 36 ± 3% compared with their baseline
values in the Lifor group; there were no responses in the CP group
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(data not shown). Percent oxygen extraction (Figure 5B) increased by
approximately 29% during CP or Lifor treatment and returned to the
baseline level on reperfusion after Lifor treatment but remained higher
after CP treatment. Oxygen consumption (Figure 6A) fell to 26 ± 6%
and 15 ± 8% of baseline during the Lifor and CP treatments and
returned to 82 ± 4% and 83 ± 6% of control after 2-hour reperfusion,
respectively. Cardiac efficiency (Figure 6B) was zero during treatments
as hearts did not beat or generate pressure and returned to 85 ± 4%
of baseline during 2-hour reperfusion with Lifor compared with its
baseline. Cardiac efficiency was zero on reperfusion after CP. Apparent
percent infarct size after Lifor treatment and 2-hour warm reperfusion
was 18.6 ± 0.1%; for the CP group infarct size was 59.5 ± 0.2%.

Figure 4

(A) Coronary flow was natural at constant pressure (55 mm Hg) before

and after treatment, and pump perfused at 20% of the natural flow during treatment.
Natural coronary flow was lower than baseline after Lifor treatment but even lower
after CP treatment. (B) During either treatment, perfusion pressure gradually
increased at the constant coronary flow of 20% baseline, indicating increased flow
resistance.
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Figure 5

(A) Before Lifor treatment (0.5 hours), coronary flow increased with

nitroprusside (NP) and adenosine (ADE) compared with baseline (BL). After treatment
(22 hours), vasodilator responses were attenuated. After CP treatment, there were no
flow responses to ADE or NP (data not shown). (B) Percent oxygen extraction
increased during Lifor treatment when Po2 was reduced from 97% to 20% (room air),
but returned to baseline levels after treatment. After CP treatment, percent oxygen
extraction remained high.
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Figure 6

(A) Oxygen consumption decreased markedly during Lifor or CP

treatment, while hearts were arrested and Po2 was lower, but was less decreased
during Lifor than during CP treatment. After treatment, oxygen consumption was lower
than baseline in both groups. (B) Cardiac efficiency (heart rate · systolic — diastolic
LVP/O2 consumption) was zero during CP and Lifor treatments and was zero after CP
treatment and lower than baseline after Lifor treatment.

Discussion
This is a second report on Lifor, a nanoparticle salt-based
solution containing amino acids and other additives as a heart
preservation solution. In our first report5 we found that Lifor was a
much better preservation solution for isolated hearts than was
ViaSpan, a commonly used preservation solution, when each were lowflow perfused at ambient air and temperature conditions for 10 h. We
found that re-circulated Lifor solution, supplemented with adenosine
and butanedione monoxime (BDM) and given both as a cardioplegic
agent and as a preservation medium, protected hearts against damage
for 10 hours at 26°C.5 Lifor-treated hearts exhibited a full return of
developed LVP and dLVP/dt minimum (relaxation), and initially, of
dLVP/dt maximum (contractility).5 Under the same experimental
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conditions as for Lifor, hearts treated with ViaSpan were completely
non-functional (no heart beat or contractile effort), with diastolic
contracture and high coronary vascular resistance during the 2-hour
reperfusion period with KR solution.
In the present study we extended the treatment time from 10 to
20 hours. CP-treated hearts were nonfunctional on reperfusion after 20
hours. In contrast, we found that low-flow perfusion of Lifor for 20
hours at ambient atmospheric and temperature conditions was
followed on reperfusion with KR solution by complete cardiac
protection for a number of variables, such as diastolic LVP, contractility
and percent oxygen extraction, and small functional declines in other
variables, such as heart rate, developed LVP, relaxation, coronary
flow, oxygen consumption and cardiac efficiency. The gradual but
small decline in function over time in constant-pressure-perfused,
isolated hearts at 37°C is well documented. We have typically noted a
fall in developed LVP of approximately 3% to 4% per hour or 9% to
12% over 3 hours.8–10 In the present study, developed LVP decreased
by 24% over the 3-hour perfusion with KR solution and 20-hour
perfusion with Lifor. In our prior study,5 15-hour perfusion with KR at
37°C resulted in a 35% decline in developed LVP. Thus, there was
effectively little fall in LVP during this 23-hour study compared with a
shorter time-control study. Decreases in heart rate and functional
indices can be largely attributed to catecholamine depletion over time.
The decline in oxygen consumption was primarily due to the
small decrease in coronary flow because percent oxygen extraction
was unchanged after compared with before treatment. Cardiac
efficiency by definition, however, was more decreased by the decline
in heart rate and developed LVP than by the fall in oxygen
consumption. Vascular resistance to flow increased progressively but
mildly during Lifor treatment. Moreover, the maximal vasodilatory
responses to nitroprusside and adenosine were depressed after Lifor
treatment compared with before Lifor treatment. These findings likely
reflect mild vascular edema because both direct vascular smooth
muscle relaxation (adenosine) and endothelium-mediated
(nitroprusside) muscle relaxation were blunted.
In our prior companion study,5 BDM and adenosine were added
because we reported improved function with these additives in a
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severe-cold-storage heart model.1,11 BDM is a non-specific reversible
inhibitor of the actinomyosin complex.12,13 In the present study we
used blebbistatin, a recently discovered inhibitor of the ATPases
associated with Class II myosin isoforms in an actin-detached state.6,7
Blebbistatin is highly specific for myosin II inhibition in cardiac and
skeletal muscle, but not in smooth muscle. Our rationale for its use
was that it might reduce or prevent diastolic contracture because the
myosin II head regions are responsible for attachment and movement
along the actin-based thin filaments that generate muscle contraction.
The apparent small infarct size in the Lifor group could
represent true infarction, but it is rather likely a result of the
inaccuracy in identifying and cutting out suspected small infarcted
areas for weighing. The values obtained are within the detection error
of the method,14 because the TTC staining-by-weight method to
determine the percentage of infarcted tissue is not reliable at lower
degrees of infarction, as indicated by the apparent 11 ± 3% infarct
size we measured after 3-hour KR perfusion without ischemia in
another study.15

Quest for Better Techniques and Solutions
During the past decade, over 600 articles have been published
on cardiac preservation techniques and solutions, but there is no
consensus on the best approaches to long-term preservation of hearts
for transplant. Although there are suitable long-term preservation
techniques for the liver and kidney, hearts cannot be well protected for
periods of more than 4 or 5 hours.16–20 More popular experimentally
tested and clinically used solutions include ViaSpan21–24 (also called UW
solution), HTK (histidine–tryptophan–ketoglutarate-based solution, or
Bretschneider’s),25,26 Celsior (anti-oxidant–based solution with
mannitol, reduced glutathione, plus high Mg2+, lactobionate and
glutamate)27–31 and STH (St Thomas’ Hospital, a high K+, high Mg+,
low Ca2+, lidocaine-containing solution)32–35; others include EuroCollins and Stanford solutions. Most of these solutions have a
“cardioplegic” (high [K+]) base to arrest the heart.
All these solutions have limitations regarding adequacy and
length of protection,36 and their protective effects are dependent on
study conditions.32,37,38 Many of the heart studies have compared one
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preservation solution with another,26,29–33,35,39–44 and with or without
additives, such as channel activators or blockers,1,11,45–49 exchange
inhibitors,50–52 anesthetics,2,9,49 nitric oxide (NO) donors,53
perfluorocarbons54 or BDM.1,30,55 For example, Celsior solution
preserved function better than ViaSpan in several studies,44,56 whereas
others found that ViaSpan was better than Celsior.29,30 HTK was found
to be more protective than ViaSpan in one study,43 whereas another
found the reverse to be true.26 A newer solution, LYPS (extracellular
type with low Ca2+ and Mg2+, added pyruvate, polyethylene glycol and
chlorpromazine), was tested using a biopsy technique for tissue
viability to evaluate the independent effects of 19 compounds found in
other preservation solutions.57 This solution was better for preserving
pig hearts stored for 8 hours at 4°C than was STH solution.57 In a rat
model (8 hours, 4°C), LYPS was better than ViaSpan (intracellulartype UW, or extracellular-type UW-1), but was equivalent to Celsior.41
Perfusion storage of hearts is rarely used clinically compared
with simple immersion into an ice-jacketed container, because it is
more complicated and costly to undertake. Perfusion storage could
require a mechanical pump, a cooling system, an oxygen supply tank
and a very large volume of non-recirculated solution to perfuse the
coronary vasculature. Moreover, to be warranted as the best
technique, perfusion preservation must lead to superior return of
function after a long period compared with simple storage, particularly
if severe cooling is to be avoided. A recent review suggested that a
perfusion system is required to effectively preserve hearts for
increasingly longer periods between explant and implant.17 Animal
studies have shown the superiority of low-flow perfusion
techniques.1,2,58,59
Another concern for long-term protection of hearts is the need
for severe hypothermia. The colder the hearts the longer they can be
protected against no-flow ischemia.8,50,52 Severe hypothermia reduces
energy demand and therefore it is useful to protect hearts
metabolically against ischemic injury during cardiac storage prior to
transplantation. Hypothermia preserves essential mechanisms during
heart transport to rapidly regenerate ATP on reperfusion by decreasing
energy utilization.
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Although hypothermia is the most effective method to preserve
hearts during ischemic storage, hypothermia itself has deleterious
effects on the contractile element and endothelial cell function as
cooling is more severe. Two of these effects include cytosolic60 and
mitochondrial3 Ca2+ loading, another is excess release of reactive
oxygen species (ROS).61 Either of these can result in mitochondrial and
cellular damage proportional to the degree and duration of
hypothermia. For example, we reported that cardiac perfusion at 17°C
before ischemia itself caused a moderate and steady-state increase in
mitochondrial Ca2+, a more reduced redox state (increased NADH),
and moderate production of ROS.3 Under different mitochondrial
conditions, either low or high tissue oxygen levels can lead to ROS
generation.4,62
Less cooling and oxygenation in cell-free preservation solutions
should be offset by methods to increase tissue oxygen and nutrient
delivery, particularly if a solution is to be recirculated to reduce the
volume of coronary perfusate required. Our goal in this experimental
model was to apply this approach, but to preserve hearts at room
temperature rather than expose them to severe hypothermia and to
do so with no added oxygen.
Transplant programs could benefit from a preservation
technique with a single solution that does not require severe cooling of
the heart or supplemental oxygen, and requires only a small volume of
coronary perfusate for transport between centers. Lifor solution has
potential in reaching this goal. A prolonged preservation time,
particularly at room temperature, would increase the available donor
pool of viable hearts and improve post-transplant outcomes. An
increase in preservation times and improvements in banking and
transport of hearts over longer distances should greatly increase the
availability of viable hearts with good tissue matches to recipients in
need.

Conclusions and Limitations
In this experimental model, which consisted of a low-flow,
coronary recirculation system at room temperature and room air, Lifor
solution maintained hearts for up to 20 hours. Simple CP solutions
rendered hearts non-viable. The experimental conditions of this study
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were set up to mimic the potential for preserving human hearts over a
long period for eventual transplant. An obvious limitation is that the
use of a small animal heart model to examine preservation solutions
may not reflect clinical conditions or use of these solutions in the large
mammalian or human heart. Future studies should determine the
optimal conditions and maximal length of protection afforded by Lifor
solution and compare Lifor with other available preservation solutions
in a large animal heart transplant model. The mechanism of protection
by nanoparticle based amino acid solutions will be a focus of future
studies.
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